Cargando…

Prognosis of Atrial Fibrillation Patients Undergoing PCI According to Anticoagulants and Antiplatelet Agents

There are limited data evaluating conformation of antithrombotic therapy usage to the guideline recommendations. We investigated clinical trends and prognoses of patients with atrial fibrillation (AF) according to anticoagulants and antiplatelet agents beyond 1 year after percutaneous coronary inter...

Descripción completa

Detalles Bibliográficos
Autores principales: Yoon, Gwang-Seok, Kim, Sun-Hwa, Kang, Si-Hyuck, Yoon, Chang-Hwan, Cho, Young-Seok, Youn, Tae-Jin, Chae, In-Ho
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8348599/
https://www.ncbi.nlm.nih.gov/pubmed/34362151
http://dx.doi.org/10.3390/jcm10153370
_version_ 1783735379183009792
author Yoon, Gwang-Seok
Kim, Sun-Hwa
Kang, Si-Hyuck
Yoon, Chang-Hwan
Cho, Young-Seok
Youn, Tae-Jin
Chae, In-Ho
author_facet Yoon, Gwang-Seok
Kim, Sun-Hwa
Kang, Si-Hyuck
Yoon, Chang-Hwan
Cho, Young-Seok
Youn, Tae-Jin
Chae, In-Ho
author_sort Yoon, Gwang-Seok
collection PubMed
description There are limited data evaluating conformation of antithrombotic therapy usage to the guideline recommendations. We investigated clinical trends and prognoses of patients with atrial fibrillation (AF) according to anticoagulants and antiplatelet agents beyond 1 year after percutaneous coronary intervention (PCI). We analyzed the records of patients with AF who underwent PCI using the Korean National Health Insurance Service database. The primary endpoint was a composite of major adverse cardiac events (MACE). The safety outcome was bleeding complications. Of 4193 participants, 81.6% received antiplatelet therapy, whereas 27.3% had oral anticoagulant (OAC)-based therapy at 18 months after PCI. The dominant therapy was dual antiplatelet therapy (37.2%), and only 3.3% of participants had OAC monotherapy. At the 1-year follow-up, the incidence of MACE was significantly lower among those receiving a combination of OAC and single antiplatelet therapy (SAPT) than among those receiving OAC monotherapy (4.78% vs. 9.42%, p = 0.017). Bleeding complication events (5.01% vs. 5.80%, p = 0.587) did not differ between the groups. In clinical practice, most patients with AF who underwent PCI continued to receive antiplatelet agents beyond 1-year post-PCI. OAC with SAPT seemed to be more effective than OAC monotherapy, without a difference in safety.
format Online
Article
Text
id pubmed-8348599
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-83485992021-08-08 Prognosis of Atrial Fibrillation Patients Undergoing PCI According to Anticoagulants and Antiplatelet Agents Yoon, Gwang-Seok Kim, Sun-Hwa Kang, Si-Hyuck Yoon, Chang-Hwan Cho, Young-Seok Youn, Tae-Jin Chae, In-Ho J Clin Med Article There are limited data evaluating conformation of antithrombotic therapy usage to the guideline recommendations. We investigated clinical trends and prognoses of patients with atrial fibrillation (AF) according to anticoagulants and antiplatelet agents beyond 1 year after percutaneous coronary intervention (PCI). We analyzed the records of patients with AF who underwent PCI using the Korean National Health Insurance Service database. The primary endpoint was a composite of major adverse cardiac events (MACE). The safety outcome was bleeding complications. Of 4193 participants, 81.6% received antiplatelet therapy, whereas 27.3% had oral anticoagulant (OAC)-based therapy at 18 months after PCI. The dominant therapy was dual antiplatelet therapy (37.2%), and only 3.3% of participants had OAC monotherapy. At the 1-year follow-up, the incidence of MACE was significantly lower among those receiving a combination of OAC and single antiplatelet therapy (SAPT) than among those receiving OAC monotherapy (4.78% vs. 9.42%, p = 0.017). Bleeding complication events (5.01% vs. 5.80%, p = 0.587) did not differ between the groups. In clinical practice, most patients with AF who underwent PCI continued to receive antiplatelet agents beyond 1-year post-PCI. OAC with SAPT seemed to be more effective than OAC monotherapy, without a difference in safety. MDPI 2021-07-29 /pmc/articles/PMC8348599/ /pubmed/34362151 http://dx.doi.org/10.3390/jcm10153370 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Yoon, Gwang-Seok
Kim, Sun-Hwa
Kang, Si-Hyuck
Yoon, Chang-Hwan
Cho, Young-Seok
Youn, Tae-Jin
Chae, In-Ho
Prognosis of Atrial Fibrillation Patients Undergoing PCI According to Anticoagulants and Antiplatelet Agents
title Prognosis of Atrial Fibrillation Patients Undergoing PCI According to Anticoagulants and Antiplatelet Agents
title_full Prognosis of Atrial Fibrillation Patients Undergoing PCI According to Anticoagulants and Antiplatelet Agents
title_fullStr Prognosis of Atrial Fibrillation Patients Undergoing PCI According to Anticoagulants and Antiplatelet Agents
title_full_unstemmed Prognosis of Atrial Fibrillation Patients Undergoing PCI According to Anticoagulants and Antiplatelet Agents
title_short Prognosis of Atrial Fibrillation Patients Undergoing PCI According to Anticoagulants and Antiplatelet Agents
title_sort prognosis of atrial fibrillation patients undergoing pci according to anticoagulants and antiplatelet agents
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8348599/
https://www.ncbi.nlm.nih.gov/pubmed/34362151
http://dx.doi.org/10.3390/jcm10153370
work_keys_str_mv AT yoongwangseok prognosisofatrialfibrillationpatientsundergoingpciaccordingtoanticoagulantsandantiplateletagents
AT kimsunhwa prognosisofatrialfibrillationpatientsundergoingpciaccordingtoanticoagulantsandantiplateletagents
AT kangsihyuck prognosisofatrialfibrillationpatientsundergoingpciaccordingtoanticoagulantsandantiplateletagents
AT yoonchanghwan prognosisofatrialfibrillationpatientsundergoingpciaccordingtoanticoagulantsandantiplateletagents
AT choyoungseok prognosisofatrialfibrillationpatientsundergoingpciaccordingtoanticoagulantsandantiplateletagents
AT yountaejin prognosisofatrialfibrillationpatientsundergoingpciaccordingtoanticoagulantsandantiplateletagents
AT chaeinho prognosisofatrialfibrillationpatientsundergoingpciaccordingtoanticoagulantsandantiplateletagents